TMS Impact on LH and FSH Hormones in Healthy Women
Transcranial Magnetic Stimulation Active
+ Transcranial Magnetic Stimulation Sham
Recherche fondamentale
Résumé
Date de début de l'étude : 1 février 2026
Date à laquelle le premier participant a commencé l'étude.This research focuses on understanding whether a non-invasive procedure called Transcranial Magnetic Stimulation (TMS) can influence hormones, specifically Luteinizing Hormone (LH) and Follicle-stimulating hormone (FSH), in healthy women during the luteal phase of their menstrual cycle. The luteal phase is the second half of the menstrual cycle, following ovulation. The study aims to explore if TMS can mimic the natural hormonal signals that stimulate LH secretion, potentially leading to a better understanding of hormonal regulation. During the study, TMS is applied to a specific area of the brain known as the Dorsolateral Prefrontal Cortex. The effect of TMS is then measured by observing changes in LH and FSH levels at six different time points. Blood samples are collected for this purpose. The primary outcome of the study is to evaluate these changes in hormone levels within each participant and compare the results between active TMS and a placebo (sham) stimulation. The study does not mention any specific risks or benefits associated with participation.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.10 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Recherche fondamentale
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Femme
Le sexe biologique des participants éligibles à s'inscrire.De 22 à 40 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Critères
Inclusion Criteria: * Healthy women aged 22-40 years with regular menstrual cycle. * In luteal phase at the time of visit. Exclusion Criteria: * Presence of any known structural brain abnormalities or tumors. * Presence of metal implants/devices in the head or neck. * Has ever had a stroke, seizure, or has a family history of epilepsy. * Head injury with loss of consciousness. * Use of hormonal contraceptives in the past 3 months. * Irregular menstrual cycles. * Diagnosed with a reproductive system disorder (e.g., PCOS, endometriosis, infertility, hypogonadism). * History of endocrine disorders such diabetes mellitus, thyroid disease, adrenal disorders, pituitary tumor or others. * Been diagnosed or received treatment for depression, anxiety disorder, schizophrenia, PTSD or bipolar disorder. * Have a history of medical disorder such liver or renal impairment, HIV/AIDS or unstable cardiac disease. * Taking any medications that affect the central nervous system such as antidepressents, antipsychotics, GLP-1 receptor agonists or hormone therapies. * Are you pregnant, planning pregnancy or breastfeeding. * Have experienced difficulties in the past during blood draws such as locating the vein, fainting or other adverse reactions. * Have any sleep disorder such as insomnia or sleep apnea. * Have fear of needles or the sight of blood. * Underwent TMS stimulation in the past and had difficulties.
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.2 groupes d'intervention sont désignés dans cette étude
50% de chances d'être dans le groupe placebo en aveugle
Groupes de traitement
Groupe I
Comparateur actifGroupe II
Dispositif fictifCentres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 1 site